Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial
- 31 July 1998
- journal article
- clinical trial
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 32 (1) , 28-34
- https://doi.org/10.1016/s0735-1097(98)00192-2
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Glycoprotein IIb/IIIa Receptor Inhibitors: Putting the EPIC, IMPACT II, RESTORE, and EPILOG Trials into PerspectiveThe American Journal of Cardiology, 1996
- Management of intracoronary thrombosis complicating percutaneous transluminal coronary angioplastyClinical Cardiology, 1996
- Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplastyJournal of the American College of Cardiology, 1996
- Novel antiplatelet therapies for treatment of patients with ischemic heart disease: Inhibitors of the platelet glycoprotein IIbIIIa integrin receptorAmerican Heart Journal, 1995
- Enhancing safety and outcomes with the newer antithrombotic and antiplatelet agentsAmerican Heart Journal, 1995
- Platelet glycoprotein II/IIIa receptor inhibitors in ischemic heart diseaseCurrent Opinion in Cardiology, 1995
- Antithrombotic therapy during percutaneous coronary interventionJournal of Thrombosis and Thrombolysis, 1995
- Quantitative angiographic and statistical methods to assess serial changes in coronary luminal diameter and implications for atherosclerosis regression trialsThe American Journal of Cardiology, 1992
- New approaches to antiplatelet therapyBlood Coagulation & Fibrinolysis, 1991
- The Thrombolysis in Myocardial Infarction (TIMI) TrialNew England Journal of Medicine, 1985